RGEN Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Repligen (NASDAQ: RGEN)
›
Repligen (NASDAQ: RGEN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 2,000 employees.
The shares were at 163.81 USD on 20 November 2026, up 13.0% over 52 weeks. Its 52-week range is 100.99 USD to 198.86 USD: the price is 17.6% below the high and 62.2% above the low.
Its market capitalisation is 10.47B USD.
Repligen reports return on equity of 2.3%, an operating margin of 8.1% and revenue up 10.9% year over year.
It holds more cash than debt, a net cash position of 170.74M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 203.21 USD is 24.1% above the current price. The next earnings report is expected on 23 February 2027.